ArticleInternational journal of nanomedicine2012
Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 55 citations in OpenAlex.
- Repurposing felodipine via hyaluronic acid-coated cetylosomes (HCCs) for parenteral active targeting of cancer: Box-Behnken statistical optimization, in vitro characterization, and in vivo studies.Drug delivery and translational research · 2026Article
- Differentiated neuroblastoma cells remain epigenetically poised for de-differentiation to an immature state.Disease models & mechanisms · 2023Article
- Multifunctional Microparticles Incorporating Gold Compound Inhibit Human Lung Cancer Xenograft.Pharmaceutical research · 2020Article
- Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands.Frontiers in chemistry · 2020Review
- A Multifunctional Hydrogel Delivers Gold Compound and Inhibits Human Lung Cancer Xenograft.Pharmaceutical research · 2019Article
- Review
- Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.Advanced pharmaceutical bulletin · 2016Review
- Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol.Scientific reports · 2016Article
- Synthesis and Cytotoxic Effect of Some Novel 1,2-Dihydropyridin-3-carbonitrile and Nicotinonitrile Derivatives.Molecules (Basel, Switzerland) · 2015Article
- Cerium oxide nanoparticles in cancer.OncoTargets and therapy · 2014Review
- Bioengineering strategies for designing targeted cancer therapies.Advances in cancer research · 2013Review
- Nanomedicine: a primer for surgeons.Pediatric surgery international · 2012Review
- Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells.International journal of nanomedicine · 2012Article
- Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy.International journal of nanomedicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDevelopment of anticancer drugs is challenging. Indeed, much research effort has been spent in the development of new drugs to improve clinical outcomes with minimal toxicity. We have previously reported that a formulation of lipid gold porphyrin nanoparticles reduced systemic drug toxicity when compared with free gold porphyrin. In this study, we investigated the delivery and treatment efficiency of PEG surface-modified lipid nanoparticles as a carrier platform.
methodsWe encapsulated antitumor drugs into PEG-modified lipid nanoparticles and these were characterized by size, zeta potential, and encapsulation efficiency. The delivery efficiency into tumor tissue was evaluated using a biodistribution study. To evaluate antitumor efficacy, gold porphyrin or camptothecin (a DNA topoisomerase I inhibitor) were encapsulated and compared using an in vivo neuroblastoma (N2A) model.
resultsWe showed that drug encapsulation into PEG-modified lipid nanoparticles enhanced the preferential uptake in tumor tissue. Furthermore, higher tumor killing efficiency was observed in response to treatment with PEG-modified lipid nanoparticles encapsulating gold porphyrin or camptothecin when compared with free gold porphyrin or free camptothecin. The in vivo antitumor effect was further confirmed by study of tumor inhibition and positive apoptosis activity. Surface modification of lipophilic nanoparticles with PEG increased the efficiency of drug delivery into tumor tissue and subsequently more effective antitumor activity.
conclusionThis specific design of a chemotherapeutic agent using nanotechnology is important in the development of a safe and effective drug in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.